You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial
|
|---|---|
| Published in |
Lancet Oncology, November 2012
|
| DOI | 10.1016/s1470-2045(12)70509-0 |
| Pubmed ID | |
| Authors |
Aimery de Gramont, Eric Van Cutsem, Hans-Joachim Schmoll, Josep Tabernero, Stephen Clarke, Malcolm J Moore, David Cunningham, Thomas H Cartwright, J Randolph Hecht, Fernando Rivera, Seock-Ah Im, György Bodoky, Ramon Salazar, Frédérique Maindrault-Goebel, Einat Shacham-Shmueli, Emilio Bajetta, Martina Makrutzki, Aijing Shang, Thierry André, Paulo M Hoff |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 22% |
| Spain | 2 | 22% |
| Gibraltar | 1 | 11% |
| Brazil | 1 | 11% |
| Japan | 1 | 11% |
| Unknown | 2 | 22% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 7 | 78% |
| Practitioners (doctors, other healthcare professionals) | 2 | 22% |
Mendeley readers
The data shown below were compiled from readership statistics for 332 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Ecuador | 2 | <1% |
| United Kingdom | 2 | <1% |
| France | 1 | <1% |
| Portugal | 1 | <1% |
| Costa Rica | 1 | <1% |
| Brazil | 1 | <1% |
| China | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 322 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 43 | 13% |
| Researcher | 43 | 13% |
| Student > Master | 42 | 13% |
| Other | 41 | 12% |
| Student > Bachelor | 28 | 8% |
| Other | 64 | 19% |
| Unknown | 71 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 156 | 47% |
| Agricultural and Biological Sciences | 27 | 8% |
| Biochemistry, Genetics and Molecular Biology | 23 | 7% |
| Pharmacology, Toxicology and Pharmaceutical Science | 11 | 3% |
| Engineering | 8 | 2% |
| Other | 21 | 6% |
| Unknown | 86 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 21. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 April 2024.
All research outputs
#1,803,494
of 26,017,215 outputs
Outputs from Lancet Oncology
#1,910
of 6,958 outputs
Outputs of similar age
#10,974
of 182,722 outputs
Outputs of similar age from Lancet Oncology
#14
of 89 outputs
Altmetric has tracked 26,017,215 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 92nd percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 6,958 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.3. This one has gotten more attention than average, scoring higher than 72% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 182,722 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 89 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 83% of its contemporaries.